Cholesterol-lowering effects of oats induced by microbially produced phenolic metabolites in metabolic syndrome: a randomized controlled trial.

Both oat diets led to significant increases in plasma ferulic acid compared to controls.

• High-dose oat diet increased plasma ferulic acid by 0.64 [0.26, 1.02], P = 0.002
• Six-week moderate oat diet increased plasma ferulic acid by 0.55 [0.21, 0.89], P = 0.003
• Study was a randomized controlled trial in individuals with metabolic syndrome (DRKS00022169)
• Two parallel-design dietary interventions were conducted simultaneously

The high-dose oat diet specifically increased plasma dihydroferulic acid.

• High-dose oat diet increased dihydroferulic acid by 1.23 [0.44, 2.01], P = 0.003
• This effect was observed in the short-term, high-dose intervention but not reported for the six-week moderate oat diet
• Dihydroferulic acid is a microbially produced phenolic metabolite

Microbial phenolic metabolites are driving factors for the cholesterol-lowering effect of oats.

• The study identified oat-microbiome-host interactions contributing to metabolic improvements
• Phenolic metabolites including ferulic acid and dihydroferulic acid were implicated as key mediators
• The findings help explain underlying mechanisms of oats' positive effects on human health that were not previously fully understood

Short-term, high-dose oat diet is a suitable approach to alleviate obesity-related lipid disorders.

• The study compared short-term high-dose and six-week moderate oat intake with respective controls
• The high-dose intervention also produced dihydroferulic acid increases not seen with moderate intake
• The trial was conducted in individuals with metabolic syndrome, a population with obesity-related lipid disorders

The study employed a parallel-design randomized controlled trial comparing two different oat supplementation regimens.

• Two randomized controlled dietary interventions were conducted in parallel design
• One intervention was short-term and high-dose; the other was six weeks in duration at moderate intake
• Each intervention had a respective control group
• Participants were individuals with metabolic syndrome
• The trial was registered under DRKS00022169